NFE2L2 and multiple sclerosis: Since NRF2-activating compounds have already been approved or are under approval for diseases such as multiple sclerosis (152–154), and Friedrich’s ataxia (155), phytochemicals that exert their actions through this transcription factor may comprise a novel therapeutic strategy against AD.